Free Trial
OTCMKTS:SNYNF

Sanofi (SNYNF) Stock Price, News & Analysis

Sanofi logo
$105.00
+0.15 (+0.14%)
(As of 10/31/2024 ET)

About Sanofi Stock (OTCMKTS:SNYNF)

Key Stats

Today's Range
$105.00
$105.00
50-Day Range
$102.35
$119.65
52-Week Range
$88.34
$119.65
Volume
557 shs
Average Volume
16,207 shs
Market Capitalization
N/A
P/E Ratio
34.04
Dividend Yield
2.67%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Sanofi Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
39th Percentile Overall Score

SNYNF MarketRank™: 

Sanofi scored higher than 39% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Sanofi is 34.04, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.70.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Sanofi is 34.04, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 131.93.

  • Percentage of Shares Shorted

  • Short Interest Ratio / Days to Cover

    Sanofi has a short interest ratio ("days to cover") of 4.
  • Change versus previous month

    Short interest in Sanofi has recently decreased by 3.23%, indicating that investor sentiment is improving.
  • Dividend Leadership

    Sanofi is a leading dividend payer. It pays a dividend yield of 4.13%, putting its dividend yield in the top 25% of dividend-paying stocks.

  • Dividend Growth

    Sanofi does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Sanofi is 90.78%. Payout ratios above 75% are not desirable because they may not be sustainable.

  • Read more about Sanofi's dividend.
  • Percentage of Shares Shorted

  • Short Interest Ratio / Days to Cover

    Sanofi has a short interest ratio ("days to cover") of 4.
  • Change versus previous month

    Short interest in Sanofi has recently decreased by 3.23%, indicating that investor sentiment is improving.
  • News Sentiment

    Sanofi has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Sanofi this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Sanofi insiders have not sold or bought any company stock.

  • Percentage Held by Institutions

    Only 30.06% of the stock of Sanofi is held by institutions.

  • Read more about Sanofi's insider trading history.
Receive SNYNF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sanofi and its competitors with MarketBeat's FREE daily newsletter.

SNYNF Stock News Headlines

DZ BANK AG Sticks to Its Hold Rating for Sanofi (SNYNF)
Sanofi (SNYNF) Receives a Sell from Deutsche Bank
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Sanofi Q3 Profit Rises - Quick Facts
Sanofi’s Strategic Moves and Financial Prospects Drive Buy Rating
See More Headlines

SNYNF Stock Analysis - Frequently Asked Questions

Sanofi's stock was trading at $99.61 at the beginning of the year. Since then, SNYNF shares have increased by 5.4% and is now trading at $105.00.
View the best growth stocks for 2024 here
.

Shares of SNYNF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - General
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:SNYNF
Fax
N/A
Employees
91,600
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (OTCMKTS:SNYNF) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners